Knight Therapeutics Inc. is a pan-American (ex-US) specialty pharmaceutical company focused on acquiring, in licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company.">
x
According to the provisions set forth in the Edital for the Unified Tender Offer for the acquisition of BDRs representing shares issued by Biotoscana Investments S.A. (currently known as “Knight Therapeutics Europe S.A.”), released to the market on July 15, 2020 (“Tender Offer”), the Offeror hereby requests the BDR Holders that selected the Offer Price in the Tender Offer and did not receive the releases made on August 12, 2022 and November 29, 2022 to send the updated information of their bank accounts as soon as possible. The information shall be sent to: ri@grupobiotoscana.com
In case the BDR Holder does not update its bank account information, the Offeror will not be able to pay the aforementioned releases from the Escrow account.
